Vaishali Pharma Limited (VAISHALI) fundamentals
Vaishali Pharma Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as VAISHALI (ISIN INE972X01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Vaishali Pharma Limited does
Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is in the pharmaceutical business, mainly dealing in active pharmaceutical ingredients, pharmaceutical formulations, surgical products, and veterinary supplements, operating in domestic and export markets. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceutical, oncology, surgical, and veterinary. The Company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/ anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, antiviral, antifungal, skeletal muscle relaxant, and anthelmintic drugs, excipients, topical steroids, corticosteroids, and enzymes. It has a global presence in Asia & Pacific, Africa, the Commonwealth of Independent States, America, and the Middle East.
Valuation and market data
| Last close | ₹8.86 |
|---|---|
| Market capitalisation | ₹121 crore |
| Enterprise value | ₹124 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.87 |
| Price to sales (TTM) | 1.09 |
| Book value per share | ₹4.75 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jan 15 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹113 crore | ₹5 crore | ₹4 crore | 0.00 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jul 2026:
| Promoters | 30.5% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 69.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.